Latest News for: asco
Edit
Rutland Herald
12 Feb 2026
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU ...
Rutland Herald
12 Feb 2026
Edit
ASCO and Conexiant Launch ASCO AI in Oncology, a Premium Digital Destination Connecting Brands with Oncology Professionals Exploring AI in Cancer Care
PR Newswire 10 Feb 2026
Edit
The Citizens
29 Jan 2026
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
The Citizens
29 Jan 2026
Edit
Independent Record
29 Jan 2026
Parker Institute for Cancer Immunotherapy Collaborates with Conquer Cancer and ASCO to Support Promising Cancer Research
Independent Record
29 Jan 2026
Endowed Young Investigator Award will fund oncologists conducting cancer research during the early stages of their careers to encourage and promote high quality immunotherapy research ... .
Edit
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
PR Newswire 13 Jan 2026
398) at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) ... The results presented at ASCO GI 2026 focus on the GC/GEJ cohort ... The presentation at ASCO GI 2026 highlights Immunofoco's ...
Edit
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM (Amplia Therapeutics Ltd)
Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128847689) .
Edit
ASCO-GI: Incyte Presentation (Incyte Corporation)
Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128853138) .
Edit
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 (Actuate Therapeutics Inc)
Public Technologies 12 Jan 2026
... for metastatic pancreatic cancer were featured in oral and poster presentations at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026.
Edit
Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026
Pharmiweb 09 Jan 2026
... untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA, taking place 8-11 January 2026.
Edit
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium (Form 8-K) (Autonomix Medical Inc)
Public Technologies 09 Jan 2026
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.
Edit
Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
PR Newswire 09 Jan 2026
The data was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026; Abstract #709 ... Phanes' data of spevatamig featured at ASCO GI 2026 can be found here.
Edit
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (Form 8-K) (Perspective Therapeutics Inc)
Public Technologies 09 Jan 2026
... expressing neuroendocrine tumors (NETs) are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI), taking place January 8-10 in San Francisco, CA.
Edit
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
PR Newswire 09 Jan 2026
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc ... Results were presented in a poster session at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, California ... About BIZENGRI (zenocutuzumab-zbco). INDICATIONS ... 2 ... 21%.
- 1
- 2
- Next page »
